Tonix Pharmaceuticals to Showcase Mpox Vaccine Platform at World Vaccine Congress Europe 2026
Event summary
- Tonix Pharmaceuticals will present on TNX-801, a horsepox-based vaccine platform for mpox and other infectious diseases, at the World Vaccine Congress Europe 2026 on October 21, 2026.
- The company will also lead a working group session on vectored vaccine platforms on October 20, 2026.
- TNX-801 is in pre-clinical development and expected to enter Phase 1 trials in 2027 pending FDA clearance.
- Tonix's infectious disease pipeline includes TNX-4800 for Lyme disease prevention and TNX-801 for mpox and smallpox.
The big picture
Tonix Pharmaceuticals is positioning itself as a key player in the infectious disease space with its TNX-801 vaccine platform. The company's participation in the World Vaccine Congress Europe 2026 underscores its strategic focus on emerging infectious diseases, particularly as global health concerns around mpox and smallpox persist. With a commercial-stage infrastructure and a pipeline of CNS and immunology products, Tonix is expanding its reach into high-unmet medical needs, potentially broadening its revenue streams and market impact.
What we're watching
- Regulatory Timing
- Whether TNX-801 secures FDA clearance for Phase 1 trials by 2027, accelerating its development timeline.
- Market Positioning
- How Tonix differentiates TNX-801 in a competitive landscape of mpox and smallpox vaccines.
- Pipeline Progress
- The pace at which Tonix advances its infectious disease pipeline, including TNX-4800 for Lyme disease.